AskGene
Developing novel cytokine prodrugs to address critical unmet medical needs in oncology and autoimmune disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $35.1m | Early VC | |
| Total Funding | 000k | ||
Related Content
AskGene Pharma is a pioneering biotechnology company specializing in the development of cytokine prodrugs aimed at improving the safety and efficacy of cancer treatments. Founded in 2012, the company operates at the intersection of science, technology, and medicine, leveraging its proprietary SmartKine platform to extend the pharmacokinetics of cytokines while minimizing peripheral toxicity. This innovation allows AskGene to create next-generation prodrugs that address unmet medical needs, particularly in the field of oncology.
The company serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies, primarily focusing on advanced gastric and gastroesophageal junction cancers. AskGene's business model revolves around the research, development, and commercialization of its proprietary cytokine prodrugs. Revenue is generated through licensing agreements, partnerships, and direct sales of its therapeutic products.
AskGene's commitment to innovation is evidenced by its world-class team of scientists and its active participation in clinical trials and medical conferences. The company recently dosed its first patient in a Phase 3 pivotal trial for ASKB589, a promising treatment for advanced gastric cancers, and presented interim results at the ASCO GI 2024 conference.
Keywords: cytokine prodrugs, cancer treatment, SmartKine platform, oncology, biotechnology, pharmacokinetics, peripheral toxicity, clinical trials, ASKB589, medical innovation.